

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**Diagnostics Assessment Programme**

**Artificial intelligence-derived software to analyse chest X-rays for  
suspected lung cancer in primary care referrals: early value  
assessment.**

**Stakeholder list**

**Manufacturer/Distributors**

Annalise.ai  
Behold.ai Technologies  
Infer Vision UK Ltd  
Lunit  
Milvue  
Siemens Healthineers

**Manufacturers with related technologies (not included in scope)**

JLK inc  
Optellum Ltd

**Professional groups**

British Thoracic Society  
Roy Castle Lung Cancer Foundation  
Royal College of Physicians  
The Society and College of Radiographers

**External Assessment Group**

Warwick Evidence, Warwick Medical School, Warwick University  
Cedar Health Technology Research Centre, Cardiff Medicentre, University Hospital  
of Wales

**Others**

Cancer Research UK  
Department of Health  
Frimley Health  
Greater Manchester Cancer Alliance and Imaging Network  
Health Improvement Scotland  
IHE UK Ltd  
Medicines and Healthcare products Regulatory Agency  
NHS England  
Queen Elizabeth University Hospital / NHS Greater Glasgow & Clyde  
University Hospitals Birmingham NHS Foundation Trust  
Welsh Government

**Definitions:****Stakeholders**

Individuals or organisations interested in a topic being evaluated by the Diagnostics Assessment Programme, and who register to become a stakeholder. For example, manufacturers of the technology, national organisations that represent healthcare professions who operate or use the results of the technology, national patient or carer organisations, NHS service providers and commissioners, statutory organisations and research organisations.

**External Assessment Group (EAG)**

An independent academic group commissioned by the NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC) that prepares a systematic review of the clinical and cost effectiveness of the technology.